Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
Inhaled Medications01:23

Inhaled Medications

Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Chronic Obstructive Pulmonary Disease-V: Management01:29

Chronic Obstructive Pulmonary Disease-V: Management

Managing Chronic Obstructive Pulmonary Disease (COPD) involves a multifaceted approach to reduce symptoms, prevent exacerbations, improve overall health status, and slow disease progression. Key strategies include lifestyle modifications, pharmacotherapy, supportive therapies, and, in some cases, surgery. Here is an overview of the primary COPD management strategies:
Smoking Cessation
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Mitochondrial dysfunction in lung ageing and disease.

European respiratory review : an official journal of the European Respiratory Society·2020
Same author

COPD 2020: new directions needed.

American journal of physiology. Lung cellular and molecular physiology·2020
Same author

Effect of a single day of increased as-needed budesonide-formoterol use on short-term risk of severe exacerbations in patients with mild asthma: a post-hoc analysis of the SYGMA 1 study.

The Lancet. Respiratory medicine·2020
Same author

Hepcidin Is Essential for Alveolar Macrophage Function and Is Disrupted by Smoke in a Murine Chronic Obstructive Pulmonary Disease Model.

Journal of immunology (Baltimore, Md. : 1950)·2020
Same author

Sex and gender: modifiers of health, disease, and medicine.

Lancet (London, England)·2020
Same author

Virus-Induced Asthma Exacerbations: SIRT1 Targeted Approach.

Journal of clinical medicine·2020

Related Experiment Video

Updated: Jun 12, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Inhaled corticosteroids in COPD: a controversy.

Peter J Barnes1

  • 1National Heart and Lung Institute, Imperial College, London, UK. p.j.barnes@imperial.ac.uk

Respiration; International Review of Thoracic Diseases
|May 27, 2010
PubMed
Summary

Inhaled corticosteroids (ICS) offer minimal benefit for COPD patients and may cause harm. Alternative anti-inflammatory treatments are needed to address corticosteroid resistance in COPD.

Area of Science:

  • Pulmonology
  • Pharmacology
  • Molecular Medicine

Background:

  • High-dose inhaled corticosteroids (ICS) are widely used for Chronic Obstructive Pulmonary Disease (COPD) management.
  • Unlike in asthma, ICS show limited efficacy in COPD and may lead to adverse effects.

Purpose of the Study:

  • To evaluate the actual benefit of ICS in COPD management.
  • To investigate the detrimental effects and molecular mechanisms of ICS unresponsiveness in COPD.

Main Methods:

  • Review of clinical trials on ICS efficacy in COPD.
  • Analysis of molecular pathways involved in corticosteroid resistance, including histone deacetylase-2 levels.

Main Results:

  • High-dose ICS, even with long-acting beta(2)-agonists (LABA), do not reduce COPD progression or mortality.

Related Experiment Videos

Last Updated: Jun 12, 2026

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System
07:28

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

  • Evidence suggests ICS may increase pneumonia risk and negatively impact bone health.
  • Reduced histone deacetylase-2 in COPD impairs ICS's anti-inflammatory action.

    • Conclusions:

    • ICS provide little to no benefit for most COPD patients and carry risks.
    • Specific patient subgroups, like those with coexisting asthma, might benefit from ICS.
    • Future therapies should target molecular pathways to overcome corticosteroid resistance in COPD.